Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ).
Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that all resolutions proposed at its 2025 first extraordinary shareholders’ meeting were approved. The meeting saw participation from a significant number of shareholders and proxies, with a total of 3,068,160,282 shares carrying voting rights. Certain shareholders abstained from voting on resolutions related to the A Share Employee Stock Ownership Scheme. The approval of these resolutions is likely to impact the company’s operational strategies and stakeholder interests.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$94.54 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a pharmaceutical company based in China, known for its development and production of a wide range of pharmaceutical products. The company is focused on innovation and has a significant presence in the pharmaceutical industry.
Average Trading Volume: 5,367,623
Current Market Cap: HK$500.1B
Learn more about 1276 stock on TipRanks’ Stock Analysis page.